Skip to main content
. 2018 Oct 21;94(1):118–132. doi: 10.1002/ajh.25301

Figure 2.

Figure 2

Overall platelet response in trials of eltrombopag, rituximab, or romiplostim. Calculated response ratios comparing the overall platelet response of patients receiving eltrombopag, rituximab, or romiplostim vs that in patients receiving placebo or standard of care